# PolyPid Ltd. (PYPD)

> Source: Nexqual · https://nexqual.com/PYPD · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, PolyPid Ltd. (PYPD), nexqual.com/PYPD" · informational, not investment advice.

**Price:** USD 4.9 (+1.45% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 4.83 · day 4.66–4.97 · 52w 3.1–5.73 · market cap $99.5M · NCM

## Key facts
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 11.75 (range 8–14).
- Total return with dividends: 1Y +46.3% vs S&P 500 +18.1%; 5Y -97.8% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD 0.27, revenue estimate $15.0M.

## Analysts
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 11.75 (low 8, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-21 | HC Wainwright & Co. | Reiterated | Buy | $13 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +46.3% | -97.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +46.5% | -53.4% |
| Volatility (annualized) | 57.7% | 93.4% |
| Max drawdown | -33.0% (Jul 2026→Jul 2026) | -99.0% (Nov 2021→Apr 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/PYPD · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt